UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 18, 2017

Health Insurance Innovations, Inc.

(Exact name of registrant as specified in its charter)

Registrant’s telephone number, including area code: (813) 397-1187

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company [X]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

On May 18, 2017, an annual restricted stock grant award of shares of Class A common stock was made to each of the non-employee directors of Health Insurance Innovations, Inc. (the “Company”) under the Company’s Long Term Incentive Plan. Each restricted stock grant award was in the amount of 2,195 shares and is scheduled to vest 50% on May 18, 2018 and 50% on May 18, 2019, subject to the terms of the grant agreement and the Long-Term Incentive Plan. The awards were made to each of Anthony Barkett, Robert S. Murley, Paul G. Gabos, and Paul E. Avery.

On May 18, 2017, the Company held its annual meeting of stockholders (the “Annual Meeting”). The Company previously filed with the SEC its Definitive Proxy Statement and related materials pertaining to the Annual Meeting on April 20, 2017. On the record date of April 7, 2017 there were 11,817,183 shares of the Company’s Class A common stock and 3,841,667 shares of the Company’s Class B common stock outstanding and eligible to vote. At the Annual Meeting, the stockholders: (i) elected the seven persons identified below to serve as directors of the Company to hold office until the Company’s 2018 Annual Meeting of Stockholders and until their successors are duly elected and qualified; (ii) approved an amendment to the Company’s Long Term Inventive Plan (“LTIP”), which (A) increased the total number of shares of the Company’s common stock reserved for issuance under the LTIP from 3,250,000 to 5,250,000 and (B) increased the aggregate maximum number of shares of common stock that may be issued pursuant to the exercise of incentive stock options; and (iii) ratified the appointment of Grant Thornton LLP as the independent auditor of the Company.

Proposal 1: Election of Directors

The final results of stockholder voting on the election of directors were as follows:

Proposal 2: Approval of an Amendment to the Company’s Long-Term Incentive Plan

The final results of stockholder voting on the approval of an amendment to the LTIP were as follows:

Proposal 3: Ratification of the appointment of Grant Thornton LLP as the Company’s Independent Auditor

The final results of stockholder voting on the ratification of the appointment of Grant Thornton as the Company’s independent auditor were as follows:

The stockholders did not vote on any other matters at the Annual Meeting.

(d) Exhibits.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 24, 2017